Market Research Logo

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Duchenne Muscular Dystrophy Market 2018 Forecast to 2023

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Duchenne Muscular Dystrophy Market 2018 Forecast to 2023

Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Scope of the Report:
This report focuses on the Duchenne Muscular Dystrophy in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
PTC Therapeutics
Sarepta Therapeutics
Bristol-Myers Squibb
ITALFARMACO
BioMarin
Daiichi Sankyo
Solid Biosciences
Summit Therapeutics
FibroGen
NS Pharma
Pfizer
ReveraGen BioPharma
Wave Life
Genethon
Santhera Pharmaceuticals

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Deflazacort
Prednisone
Others

Market Segment by Applications, can be divided into
Male
Female

There are 15 Chapters to deeply display the global Duchenne Muscular Dystrophy market.

Chapter 1, to describe Duchenne Muscular Dystrophy Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Duchenne Muscular Dystrophy, with sales, revenue, and price of Duchenne Muscular Dystrophy, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Duchenne Muscular Dystrophy, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Duchenne Muscular Dystrophy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Duchenne Muscular Dystrophy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


1 Market Overview
1.1 Duchenne Muscular Dystrophy Introduction
1.2 Market Analysis by Type
1.2.1 Deflazacort
1.2.2 Prednisone
1.2.3 Others
1.3 Market Analysis by Applications
1.3.1 Male
1.3.2 Female
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 PTC Therapeutics
2.1.1 Business Overview
2.1.2 Duchenne Muscular Dystrophy Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sarepta Therapeutics
2.2.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb
2.3.1 Business Overview
2.3.2 Duchenne Muscular Dystrophy Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 ITALFARMACO
2.4.1 Business Overview
2.4.2 Duchenne Muscular Dystrophy Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 ITALFARMACO Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 BioMarin
2.5.1 Business Overview
2.5.2 Duchenne Muscular Dystrophy Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 BioMarin Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Daiichi Sankyo
2.6.1 Business Overview
2.6.2 Duchenne Muscular Dystrophy Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Daiichi Sankyo Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Solid Biosciences
2.7.1 Business Overview
2.7.2 Duchenne Muscular Dystrophy Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Solid Biosciences Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Summit Therapeutics
2.8.1 Business Overview
2.8.2 Duchenne Muscular Dystrophy Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Summit Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 FibroGen
2.9.1 Business Overview
2.9.2 Duchenne Muscular Dystrophy Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 FibroGen Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 NS Pharma
2.10.1 Business Overview
2.10.2 Duchenne Muscular Dystrophy Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 NS Pharma Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Pfizer
2.11.1 Business Overview
2.11.2 Duchenne Muscular Dystrophy Type and Applications
2.11.2.1 Type 1
2.11.2.2 Type 2
2.11.3 Pfizer Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 ReveraGen BioPharma
2.12.1 Business Overview
2.12.2 Duchenne Muscular Dystrophy Type and Applications
2.12.2.1 Type 1
2.12.2.2 Type 2
2.12.3 ReveraGen BioPharma Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Wave Life
2.13.1 Business Overview
2.13.2 Duchenne Muscular Dystrophy Type and Applications
2.13.2.1 Type 1
2.13.2.2 Type 2
2.13.3 Wave Life Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Genethon
2.14.1 Business Overview
2.14.2 Duchenne Muscular Dystrophy Type and Applications
2.14.2.1 Type 1
2.14.2.2 Type 2
2.14.3 Genethon Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Santhera Pharmaceuticals
2.15.1 Business Overview
2.15.2 Duchenne Muscular Dystrophy Type and Applications
2.15.2.1 Type 1
2.15.2.2 Type 2
2.15.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Duchenne Muscular Dystrophy Market Competition, by Manufacturer
3.1 Global Duchenne Muscular Dystrophy Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Duchenne Muscular Dystrophy Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Duchenne Muscular Dystrophy Manufacturer Market Share in 2017
3.4.2 Top 5 Duchenne Muscular Dystrophy Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Duchenne Muscular Dystrophy Market Analysis by Regions
4.1 Global Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Regions
4.1.1 Global Duchenne Muscular Dystrophy Sales by Regions (2013-2018)
4.1.2 Global Duchenne Muscular Dystrophy Revenue by Regions (2013-2018)
4.2 North America Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2013-2018)
5 North America Duchenne Muscular Dystrophy by Countries, Type, Application and Manufacturers
5.1 North America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
5.1.1 North America Duchenne Muscular Dystrophy Sales by Countries (2013-2018)
5.1.2 North America Duchenne Muscular Dystrophy Revenue by Countries (2013-2018)
5.1.3 United States Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
5.1.4 Canada Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
5.1.5 Mexico Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
5.2 North America Duchenne Muscular Dystrophy Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2017)
5.2.2 North America Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2017)
5.3 North America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Duchenne Muscular Dystrophy Sales and Sales Share by Type (2013-2018)
5.3.2 North America Duchenne Muscular Dystrophy Revenue and Revenue Share by Type (2013-2018)
5.4 North America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Duchenne Muscular Dystrophy Sales and Sales Share by Application (2013-2018)
5.4.2 North America Duchenne Muscular Dystrophy Revenue and Revenue Share by Application (2013-2018)
6 Europe Duchenne Muscular Dystrophy by Countries, Type, Application and Manufacturers
6.1 Europe Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
6.1.1 Europe Duchenne Muscular Dystrophy Sales by Countries (2013-2018)
6.1.2 Europe Duchenne Muscular Dystrophy Revenue by Countries (2013-2018)
6.1.3 Germany Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.1.4 UK Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.1.5 France Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.1.6 Russia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.1.7 Italy Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
6.2 Europe Duchenne Muscular Dystrophy Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2017)
6.2.2 Europe Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2017)
6.3 Europe Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Duchenne Muscular Dystrophy Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Duchenne Muscular Dystrophy Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Duchenne Muscular Dystrophy Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Duchenne Muscular Dystrophy Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Duchenne Muscular Dystrophy by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Duchenne Muscular Dystrophy Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue by Countries (2013-2018)
7.1.3 China Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.1.4 Japan Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.1.5 Korea Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.1.6 India Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Duchenne Muscular Dystrophy Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Duchenne Muscular Dystrophy Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Duchenne Muscular Dystrophy Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue and Revenue Share by Application (2013-2018)
8 South America Duchenne Muscular Dystrophy by Countries, Type, Application and Manufacturers
8.1 South America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
8.1.1 South America Duchenne Muscular Dystrophy Sales by Countries (2013-2018)
8.1.2 South America Duchenne Muscular Dystrophy Revenue by Countries (2013-2018)
8.1.3 Brazil Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
8.1.4 Argentina Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
8.1.5 Colombia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
8.2 South America Duchenne Muscular Dystrophy Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2017)
8.2.2 South America Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2017)
8.3 South America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Duchenne Muscular Dystrophy Sales and Sales Share by Type (2013-2018)
8.3.2 South America Duchenne Muscular Dystrophy Revenue and Revenue Share by Type (2013-2018)
8.4 South America Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Duchenne Muscular Dystrophy Sales and Sales Share by Application (2013-2018)
8.4.2 South America Duchenne Muscular Dystrophy Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Duchenne Muscular Dystrophy by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.1.4 UAE Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.1.5 Egypt Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.1.7 South Africa Duchenne Muscular Dystrophy Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Duchenne Muscular Dystrophy Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Duchenne Muscular Dystrophy Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Duchenne Muscular Dystrophy Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Duchenne Muscular Dystrophy Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue and Revenue Share by Application (2013-2018)
10 Global Duchenne Muscular Dystrophy Market Segment by Type
10.1 Global Duchenne Muscular Dystrophy Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Duchenne Muscular Dystrophy Sales and Market Share by Type (2013-2018)
10.1.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2013-2018)
10.2 Deflazacort Sales Growth and Price
10.2.1 Global Deflazacort Sales Growth (2013-2018)
10.2.2 Global Deflazacort Price (2013-2018)
10.3 Prednisone Sales Growth and Price
10.3.1 Global Prednisone Sales Growth (2013-2018)
10.3.2 Global Prednisone Price (2013-2018)
10.4 Others Sales Growth and Price
10.4.1 Global Others Sales Growth (2013-2018)
10.4.2 Global Others Price (2013-2018)
11 Global Duchenne Muscular Dystrophy Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2013-2018)
11.2 Male Sales Growth (2013-2018)
11.3 Female Sales Growth (2013-2018)
12 Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.1 Global Duchenne Muscular Dystrophy Sales, Revenue and Growth Rate (2018-2023)
12.2 Duchenne Muscular Dystrophy Market Forecast by Regions (2018-2023)
12.2.1 North America Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.2 Europe Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.3 Asia-Pacific Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.4 South America Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.2.5 Middle East and Africa Duchenne Muscular Dystrophy Market Forecast (2018-2023)
12.3 Duchenne Muscular Dystrophy Market Forecast by Type (2018-2023)
12.3.1 Global Duchenne Muscular Dystrophy Sales Forecast by Type (2018-2023)
12.3.2 Global Duchenne Muscular Dystrophy Market Share Forecast by Type (2018-2023)
12.4 Duchenne Muscular Dystrophy Market Forecast by Application (2018-2023)
12.4.1 Global Duchenne Muscular Dystrophy Sales Forecast by Application (2018-2023)
12.4.2 Global Duchenne Muscular Dystrophy Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report